In animal models of asthma, AD, and acute lung inflammation, the compound reduced key type 2 inflammatory biomarkers and showed therapeutic efficacy comparable to anti–IL-4/IL-13 biologics. This evidence concerns the gene IL4 and Alzheimer disease.